Short Interest in CalciMedica Inc. (NASDAQ:CALC) Grows By 91.4%

CalciMedica Inc. (NASDAQ:CALC) was the target of a large growth in short interest in June. As of June 15th, there was short interest totaling 276,326 shares, a growth of 91.4% from the May 31st total of 144,356 shares. Based on an average daily trading volume, of 459,271 shares, the short-interest ratio is presently 0.6 days. Currently, 3.0% of the company’s stock are sold short.

Insider Buying and Selling

In other news, Director Fred A. Middleton purchased 248,972 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were acquired at an average cost of $0.80 per share, with a total value of $199,177.60. Following the purchase, the director owned 1,063,272 shares in the company, valued at $850,617.60. This represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 41.55% of the stock is owned by insiders.

Institutional Trading of CalciMedica

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its holdings in shares of CalciMedica by 45.0% in the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after purchasing an additional 39,775 shares in the last quarter. 180 Wealth Advisors LLC boosted its position in shares of CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after buying an additional 94,650 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in CalciMedica during the fourth quarter worth $506,000. Jane Street Group LLC bought a new stake in CalciMedica during the fourth quarter worth $127,000. Finally, PVG Asset Management Corp purchased a new stake in CalciMedica in the 4th quarter valued at $302,000.

Analyst Upgrades and Downgrades

Separately, Oppenheimer decreased their price objective on CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a report on Thursday, March 5th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, CalciMedica presently has an average rating of “Hold” and an average price target of $10.00.

CalciMedica Price Performance

Shares of NASDAQ:CALC traded up $0.07 during midday trading on Wednesday, hitting $1.10. 655,009 shares of the company’s stock were exchanged, compared to its average volume of 1,243,422. CalciMedica has a 12 month low of $0.46 and a 12 month high of $7.20. The company has a market cap of $17.46 million, a PE ratio of -0.84 and a beta of 0.97. The stock has a 50 day moving average price of $0.73 and a 200-day moving average price of $1.87.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.